Total Voting Rights

 

TIDMLMT 
 
RNS Number : 0460O 
Lombard Medical Technologies PLC 
27 February 2009 
 

Press information 
 
 
Lombard Medical Technologies PLC 
("Lombard Medical" or "Company") 
 
 
Total Voting Rights 
 
 
London, UK, 27 February 2009: Lombard Medical (AIM: LMT) announces that for the 
purposes of the Disclosure and Transparency Rules, the Company's total issued 
share capital at the date of this announcement is 791,304,766 ordinary shares of 
1p each, with one voting right per share. There are no shares held in treasury. 
The total number of voting rights in the Company is therefore 791,304,766. 
The above figure of 791,304,766 shares may be used by shareholders as a 
denominator for the calculations by which they will determine if they are 
required to notify their interest in, or change to their interest in, the 
Company, under the Disclosure and Transparency Rules. 
 
 
- Ends - 
Enquiries: 
+---------------------------------------+-------------------------------+ 
| Lombard Medical Technologies PLC      | Tel: [phone]     | 
+---------------------------------------+-------------------------------+ 
| Simon Neathercoat, Non-executive      |                               | 
| Chairman                              |                               | 
+---------------------------------------+-------------------------------+ 
| Brian Howlett, Chief Executive        |                               | 
| Officer                               |                               | 
+---------------------------------------+-------------------------------+ 
| Tim Hall, Finance Director            |                               | 
+---------------------------------------+-------------------------------+ 
|                                       |                               | 
+---------------------------------------+-------------------------------+ 
| Financial Dynamics                    | Tel: [phone]     | 
+---------------------------------------+-------------------------------+ 
| David Yates / Susan Quigley           |                               | 
+---------------------------------------+-------------------------------+ 
|                                       |                               | 
+---------------------------------------+-------------------------------+ 
| Nomura Code Securities Limited        | Tel: [phone]     | 
+---------------------------------------+-------------------------------+ 
| Juliet Thompson / Richard Potts       |                               | 
+---------------------------------------+-------------------------------+ 
 
 
Notes to editors 
 
 
About Lombard Medical 
Lombard Medical Technologies PLC is a medical devices group developing stent 
grafts and other medical products for use in the treatment of vascular disease. 
The Company's lead product, Aorfix(TM), is an endovascular stent graft for the 
treatment of abdominal aortic aneurysms (AAAs), a balloon-like enlargement of 
the aorta which, if untreated, may rupture and cause death. Approximately 1.7 
million people have AAAs in the US where it is the 13th largest cause of death. 
The market for endovascular stent grafts for the treatment of AAA is currently 
worth over $600 million and is expected to grow to around a $1 billion by 2010. 
Aorfix(TM) is currently being commercialised in the EU, with a pivotal clinical 
trial ongoing in the USA. 
The Company's Polymer Coatings Division has developed a novel hydrophilic 
surface treatment to reduce friction on catheters called GlideMax(TM), which is 
available for licensing, and is using its polymer coating technology in a number 
of research collaborations developing novel products for the $5 billion 
drug-eluting stent market. 
The Company is headquartered in Oxfordshire, with operations in Yorkshire, 
Ayrshire and Boston, USA. 
Further background on the Company can be found at www.lombardmedical.com. 
 
 
 
 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 TVREASAXAEDNEFE